Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Policy & Politics

Massachusetts Group, Others Push for HIV Prevention Pill

From U.S. Centers for Disease Control and Prevention

October 25, 2011

The AIDS Action Committee of Massachusetts and a dozen other AIDS-fighting groups are asking federal regulators to quickly review the use of a daily pill to prevent new HIV infections among men who have sex with men and among transgender women, two groups CDC estimates account for more than one-half of all new HIV infections in the United States. The organizations say the U.S. Food and Drug Administration and Gilead Sciences Inc., maker of the HIV treatment Truvada, should not delay their review of the daily use of the drug by these populations over doubts about its efficacy in heterosexuals.

Back to other news for October 2011

Adapted from:
Associated Press
10.19.2011

  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
 
See Also
Two New Studies Support Use of PrEP for HIV Prevention Among Heterosexual Men and Women
CDC Statement: CDC Trial and Another Major Study Find PrEP Can Reduce Risk of HIV Infection Among Heterosexuals
U. Washington Statement: Pivotal Study Finds That HIV Medications Are Highly Effective as Prophylaxis Against HIV Infection in Men and Women in Africa
iPrEx Statement: Two Major Studies Prove HIV Pre-Exposure Prophylaxis (PrEP) Works in in Heterosexual Women and Men; Build on iPrEx Data Showing PrEP Reduces HIV Infections in Men Who Have Sex With Men
More News and Research on HIV Medications for HIV Prevention
No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

 

Advertisement